Human cytomegalovirus (HCMV) is one of the opportunistic infections associated with significant morbidity and mortality among HIV/AIDS patients especially before introduction of antiretroviral therapy (ART). Little is known regarding the humoral immune response against HCMV in relation to CD4 counts among HIV infected individuals. A total of 90 achieved sera from HIV infected patients attending Bugando Medical centre care and treatment centre (CTC) aged 18 years and above were retrieved and analyzed. Sociodemographic data were collected using structured data collection tool. Detection of specific HCMV antibodies was done using Indirect Enzyme Linked Immunosorbent Assay (ELISA). Data were analyzed by using STATA version 11. A total of 90 HIV infected patients were enrolled in the study whereby 36(40%) had immunological treatment failure.
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Human cytomegalovirus (HCMV) has been known to establish latency following primary subclinical infections in immunocompetent individuals [1, 2] . In these individuals reactivation may occur periodically without any observed sequels. However, in deficiency of host-derived antiviral immune responses reactivation often cause pathological changes that may results into invasive disease [3] [4] [5] .
Long-lasting immunity in response to HCMV primary infection serves to control subsequent HCMV reactivation in the host which is essential for preventing uncontrolled viral replication and serious HCMV disease [6] . In this context humoral and cell mediated immunity plays a crucial role in sustaining the balance between maintenance and reactivation which may results into pathological changes among these patients in case of any disruption. Human immunodeficiency virus (HIV) infected patients can control this balance when they start therapy as the CD4 counts and other immunological markers increases. However, in patients with immunological treatment failure it has been hypothesized that low [14, 15] . In comparison to previous studies the reported prevalence of HCMV IgM antibodies was lower [16] . As per WHO citeria [17], the median CD4 counts were significantly higher among patients who had immunological treatment success at 6 months and 12 months (Table 1) . On the regression analysis there was no significant correlation between baseline CD4 counts and HCMV IgG index value (p=0.45). This could be due to sigfnificant low CD4 counts which might have contributed to the impared function of CD4 due to high viral load [17, 18] . Correlation with bordeline significant between CD4 counts and HCMV IgG index values was oberved at 6 months on HAART while significant correlation between CD4 counts and HCMV IgG index value was observed at 12 months on HAART, p=0.04, (Figure 1 ). Generally we observed that at 6 months and 12 months there was significant relation between IgG titers and CD4 counts in the treatment success group. This could be due to increase immunocompetency which is associated with HAART treatment. Previous study [19] showed that the increase in CD4 count and function is associated with increased humoral response.
In addition no significant difference was observed on the HCMV antibody titers in relation to age in both groups, signifying that HIV and CD4 counts are only factors influencing HCMV humoral immune responses.
In conclusion significant proportion of HIV infected individuals were 
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